Author: Shiakolas, Andrea R.; Johnson, Nicole; Kramer, Kevin J.; Suryadevara, Naveenchandra; Wrapp, Daniel; Periasamy, Sivakumar; Pilewski, Kelsey A.; Raju, Nagarajan; Nargi, Rachel; Sutton, Rachel E.; Walker, Lauren; Setliff, Ian; Crowe, James E.; Bukreyev, Alexander; Carnahan, Robert H.; McLellan, Jason S.; Georgiev, Ivelin S.
Title: Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking Cord-id: 1b6dkvdj Document date: 2021_6_30
ID: 1b6dkvdj
Snippet: SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. Here, we show that incorporating antibody–ligand blocking as part of LIBRA-seq, the high-throughput sequencing platform for antibody discovery, results in efficient identification of ultra-potent neutralizing antibod
Document: SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. Here, we show that incorporating antibody–ligand blocking as part of LIBRA-seq, the high-throughput sequencing platform for antibody discovery, results in efficient identification of ultra-potent neutralizing antibodies against SARS-CoV-2. LIBRA-seq with ligand blocking is a general platform for functional antibody discovery targeting the disruption of antigen–ligand interactions.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date